Immunic, inc. reports third quarter 2023 financial results and provides corporate update

– positive interim analysis from phase 2 calliper trial showed improvements in serum neurofilament light chain for vidofludimus calcium, consistent throughout the overall progressive multiple sclerosis population and all subtypes – –  notice of allowance for united states patent protecting the treatment of relapsing multiple sclerosis with vidofludimus and its salts bolsters multilayered intellectual property position – – $59.7 million in cash and cash equivalents as of september 30, 2023 expected to fund immunic into september of 2024 – – webcast to be held today, november 14, 2023, at 8:00 am et – new york , nov. 14, 2023 /prnewswire/ --  immunic, inc.  (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced financial results for the third quarter ended september 30, 2023, and provided a corporate update. "we have continued to make tangible progress on the clinical development of our lead asset, nuclear receptor related 1 (nurr1) activator, vidofludimus calcium (imu-838).
IMUX Ratings Summary
IMUX Quant Ranking